CY1119642T1 - Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου - Google Patents

Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου

Info

Publication number
CY1119642T1
CY1119642T1 CY20171100426T CY171100426T CY1119642T1 CY 1119642 T1 CY1119642 T1 CY 1119642T1 CY 20171100426 T CY20171100426 T CY 20171100426T CY 171100426 T CY171100426 T CY 171100426T CY 1119642 T1 CY1119642 T1 CY 1119642T1
Authority
CY
Cyprus
Prior art keywords
brain tumor
csf
suspensions
tumor therapy
treatment
Prior art date
Application number
CY20171100426T
Other languages
English (en)
Inventor
Dylan DANIEL
Johanna JOYCE
James Sutton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1119642T1 publication Critical patent/CY1119642T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια ένωση του χημικού τύπου I, όπου το R1 είναι μια αλκύλ πυραζόλη ή μια αλκύλ καρβοξαμίδη, και το R2 είναι ένα υδροξυκυκλοαλκύλ, ή ένα φαρμακευτικώς αποδεκτό άλας αυτών, και συνθέσεις που περιέχουν αυτές τις ενώσεις, για χρήση στην θεραπεία ενός όγκου του εγκεφάλου, συγκεκριμένα του γλοιοβλαστώματος. Η εφεύρεση παρέχει αποτελεσματική θεραπεία ενός όγκου του εγκεφάλου και μπορεί να χρησιμοποιηθεί μέσω χορήγησης από του στόματος μιας ένωσης του χημικού τύπου I όπως περιγράφηκε εκτενώς στο παρόν. Γονιδιακές υπογραφές που σχετίζονται με επιτυχημένη θεραπεία χρησιμοποιώντας αυτές τις μεθόδους επίσης εσωκλείονται.
CY20171100426T 2011-05-05 2017-04-10 Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου CY1119642T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482723P 2011-05-05 2011-05-05
US201261624861P 2012-04-16 2012-04-16
PCT/US2012/036589 WO2012151523A1 (en) 2011-05-05 2012-05-04 Csf-1r inhibitors for treatment of brain tumors

Publications (1)

Publication Number Publication Date
CY1119642T1 true CY1119642T1 (el) 2018-04-04

Family

ID=46062775

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100426T CY1119642T1 (el) 2011-05-05 2017-04-10 Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου

Country Status (19)

Country Link
US (3) US20140065141A1 (el)
EP (1) EP2704713B1 (el)
JP (1) JP6046702B2 (el)
KR (1) KR101938431B1 (el)
CN (1) CN103501785B (el)
BR (1) BR112013028095B1 (el)
CA (1) CA2834696C (el)
CY (1) CY1119642T1 (el)
DK (1) DK2704713T3 (el)
EA (1) EA023999B1 (el)
ES (1) ES2622527T3 (el)
HR (1) HRP20170593T1 (el)
HU (1) HUE032754T2 (el)
LT (1) LT2704713T (el)
MX (1) MX347616B (el)
PL (1) PL2704713T3 (el)
PT (1) PT2704713T (el)
SI (1) SI2704713T1 (el)
WO (1) WO2012151523A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147631A1 (en) * 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
WO2016182988A1 (en) 2015-05-08 2016-11-17 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
EA039951B1 (ru) * 2015-05-27 2022-03-31 Юсб Биофарма Спрл Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
EP3973988A1 (en) 2015-11-04 2022-03-30 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
EP3526217B1 (en) * 2016-10-14 2023-04-19 Novartis AG Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide
CA3037116A1 (en) * 2016-10-14 2018-04-19 Novartis Ag Methods for treating ocular disease using inhibitors of csf-1r
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
MA48781A (fr) 2017-06-02 2020-04-08 Juno Therapeutics Inc Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
EP3644721A1 (en) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2020036987A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
SG11202105380RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
CN110468210A (zh) * 2019-09-12 2019-11-19 暨南大学 Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用
CN115398231A (zh) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
BR112023004719A2 (pt) * 2020-09-21 2023-04-18 Hutchison Medipharma Ltd Compostos heteroaromáticos e usos dos mesmos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100721656B1 (ko) 2005-11-01 2007-05-23 주식회사 엘지화학 유기 전기 소자
JP2009533405A (ja) * 2006-04-14 2009-09-17 アストラゼネカ アクチボラグ Ｃｓｆ−１ｒキナーゼ阻害剤としての４−アニリノキノリン−３−カルボキサミド
MX2008013427A (es) 2006-04-19 2008-11-04 Novartis Ag Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
RU2475483C2 (ru) 2006-04-20 2013-02-20 Янссен Фармацевтика Н.В. Ингибиторы с-fms киназы
EP2152700B1 (en) * 2007-05-21 2013-12-11 Novartis AG Csf-1r inhibitors, compositions, and methods of use

Also Published As

Publication number Publication date
CA2834696A1 (en) 2012-11-08
US20190030013A1 (en) 2019-01-31
AU2012250574B2 (en) 2016-07-07
HUE032754T2 (en) 2017-10-30
JP6046702B2 (ja) 2016-12-21
JP2014513136A (ja) 2014-05-29
PT2704713T (pt) 2017-04-24
MX2013012939A (es) 2014-02-27
WO2012151523A1 (en) 2012-11-08
EP2704713B1 (en) 2017-01-18
EA023999B1 (ru) 2016-08-31
HRP20170593T1 (hr) 2017-07-14
LT2704713T (lt) 2017-04-25
BR112013028095B1 (pt) 2020-03-03
AU2012250574A8 (en) 2016-07-28
BR112013028095A2 (pt) 2016-12-27
DK2704713T3 (en) 2017-04-24
CA2834696C (en) 2019-07-23
EP2704713A1 (en) 2014-03-12
EA201391629A1 (ru) 2016-01-29
AU2012250574A1 (en) 2013-11-28
US10537561B2 (en) 2020-01-21
ES2622527T3 (es) 2017-07-06
CN103501785B (zh) 2016-10-26
MX347616B (es) 2017-05-04
CN103501785A (zh) 2014-01-08
KR20140029475A (ko) 2014-03-10
US20150306085A1 (en) 2015-10-29
SI2704713T1 (sl) 2017-05-31
KR101938431B1 (ko) 2019-01-14
PL2704713T3 (pl) 2017-08-31
US20140065141A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
CY1119642T1 (el) Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1122498T1 (el) Δευτεριωμενα παραγωγα ιβακαφτορης
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
CY1121320T1 (el) Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
CY1122712T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ
CY1121763T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1120104T1 (el) Αναστολεις της syk
CY1121231T1 (el) Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης
CY1119939T1 (el) Παραγωγα 2,3-διϋδρο-βενζο[1,4]οξαζιν και σχετικες ενωσεις οπως αναστολεις φωσφοϊνοσιτινης-3 κινασης (ρι3κ) για τη θεραπεια παραδειγματος χαρην της ρευματοειδους αρθριτιδας
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1123616T1 (el) 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
EA201291409A1 (ru) Производные индолизина, способ их получения и их терапевтическое применение
EA201391568A1 (ru) Новые производные имидазола, подходящие для лечения артрита
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
EA201291414A1 (ru) Имидазопиридиновые производные, способ их получения и терапевтическое использование
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
CY1118371T1 (el) Αναστολεις του iap